Revenue
2024
2025
AtaiBeckley Inc. (ATAI)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Revenue | $4.1M | $308,000 |
| Research & development | $53.1M | $55.5M |
| Operating expenses | $648.1M | $103.0M |
| Operating income | −$644.1M | −$102.7M |
| EBITDAderived | −$643.0M | −$102.2M |
| Net income | −$660.0M | −$149.3M |
| Basic EPSper diluted share | -$2.91 | -$0.93 |
| Diluted EPSper diluted share | -$2.91 | -$0.93 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 · 10b5-1 | Kochendoerfer GerdChief Operating Officer | SellCommon Stock | 50.0K | $5.00 | $250.0K | 0 |
| Jun 25, 2026Form 4 · 10b5-1 | Craig Kevin JamesChief Medical Officer | SellCommon Stock | 42.6K | $4.51 | $192.0K | 8.4K |
| Apr 20, 2026Form 4 · 10b5-1 | Craig Kevin JamesChief Medical Officer | SellCommon Stock | 42.6K | $5.00 | $212.9K | 8.4K |
| Mar 20, 2026Form 4 · 10b5-1 | Craig Kevin JamesChief Medical Officer | SellCommon Stock | 100.0K | $3.55 | $355.0K | 8.4K |
| Jan 2, 2026Form 4 | Feilding-Mellen CosmoDirector | SellCommon Stock | 39.6K | $3.90 | $154.4K | 7.66M |